This article is more than 5 years old. Information may no longer be current.

Aerie announces $75 million public stock offering

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Aerie Pharmaceuticals has begun a registered underwritten public offering of $75 million of shares of its common stock, according to a company press release.

From the date of the offering, the underwriter will have a 30-day option to purchase up to an additional $11.25 million of shares.

The company will use the proceeds of the offering to fund its commercialization programs for Rhopressa and Roclatan in North America, as well as clinical and commercialization efforts outside of North America, and to develop other potential pipeline opportunities, the release said.